Sign Up to like & get
recommendations!
0
Published in 2025 at "Advanced Science"
DOI: 10.1002/advs.202503682
Abstract: Acute Myeloid Leukemia (AML) remains a formidable clinical challenge, predominantly due to the emergence of resistance to existing therapeutic regimens, including BCL‐2 inhibitors like Venetoclax. Here, a novel approach is introduced by engineering BH3 mimetics…
read more here.
Keywords:
bh3;
mcl bcl;
acute myeloid;
engineering bh3 ... See more keywords